Share on StockTwits

Auspex Pharmaceuticals (NASDAQ:ASPX) major shareholder Ventures Vii Lp Cmea sold 1,700 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $20.56, for a total transaction of $34,952.00. Following the sale, the insider now directly owns 3,771,280 shares of the company’s stock, valued at approximately $77,537,517. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

ASPX has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus raised their price target on shares of Auspex Pharmaceuticals from $39.00 to $40.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. Analysts at Robert W. Baird raised their price target on shares of Auspex Pharmaceuticals from $34.00 to $42.00 in a research note on Friday, July 11th. They now have an “outperform” rating on the stock.

Shares of Auspex Pharmaceuticals (NASDAQ:ASPX) traded up 3.10% during mid-day trading on Tuesday, hitting $21.63. The stock had a trading volume of 69,336 shares. Auspex Pharmaceuticals has a one year low of $13.25 and a one year high of $35.78. The stock’s 50-day moving average is $19.86 and its 200-day moving average is $22.91. The company’s market cap is $496.2 million.

Auspex Pharmaceuticals (NASDAQ:ASPX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.33) by $0.12. On average, analysts predict that Auspex Pharmaceuticals will post $-2.03 earnings per share for the current fiscal year.

Auspex Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.